MedTrace Logo

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

NCT06594939 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-05-01

No results posted yet for this study

Summary

This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for elderly patients with a new diagnosis of diffuse large B-cell lymphoma.

Conditions

  • Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG

Polatuzumab Vedotin

A combination of a monoclonal antibody and a chemotherapy drug.

DRUG

Mosunetuzumab

A monoclonal antibody.

DRUG

Cyclophosphamide

Chemotherapy drug, alkylating agent.

DRUG

Doxorubicin

Chemotherapy drug, anthracycline antibiotic.

DRUG

Prednisone

Steroid, anti-inflammatory

OTHER

Pegfilgrastim

Granulocyte stimulating factor, biologic response modifier.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Nirav Shah, MD · Medical College of Wisconsin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-06-30
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06594939 on ClinicalTrials.gov